Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752552 | 0.84 | IFNAR1 (0.58) | CHRM2IFNAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14476995 | 0.81 | CHRM2 (0.79) | CHRM2SLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL10282552 | 0.79 | CHRM2 (0.66) | CHRM2IFNAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31265560 | 0.78 | SLC6A4 (0.57) | IFNAR1SLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL8016874 | 0.78 | SLC6A4 (0.57) | IFNAR1SLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL24018766 | 0.78 | IFNAR1 (0.51) | CHRM2IFNAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14513499 | 0.78 | IFNAR1 (0.65) | IFNAR1SLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL10245653 | 0.78 | CHRM2 (0.54) | CHRM2IFNAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11753290 | 0.78 | SLC6A4 (0.69) | IFNAR1SLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL11630699 | 0.76 | IFNAR1 (0.68) | IFNAR1SLC6A2SLC6A4SLC6A3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754192-B2 | Compositions comprising homogeneously glycosylated erythropoietin | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-06-17 | — | — | US | disclosed |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| EP-1730141-B1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-7538141-B2 | Compounds for the treatment of diseases | PFIZER INC. | 2009-05-26 | — | — | US | disclosed |
| US-7351742-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| EP-1708992-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| EP-1758861-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| EP-1593671-A1 | DPP-IV inhibitors | Graffinity Pharmaceuticals AG (DE) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | CHRM2 653/4885IFNAR1 827/4885SLC6A2 1134/4885 |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | EPOR, LIFR, LNPEP | CHRM2 4410/4885IFNAR1 1180/4885SLC6A2 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.